Executive Summary
ALG-000184
• AASLD data show that daily oral dosing with 300 mg ALG-000184±ETV x ≤48
weeks in untreated HBeAg+ CHB pts results in:
– A favorable safety profile
– Greater suppression of HBV DNA and RNA vs. ETV alone (1st MOA)
– No viral breakthrough when ALG-000184 is given as monotherapy x ≤44 weeks
– Multi-log reductions in HBsAg, HBeAg, & HBcrAg, which appear to be mediated by
ALG-000184 (2nd MOA)
• ALG-000184 appears to lower cccDNA levels via 1st and 2nd MOA
• ALG-000184 may play an important role in enhancing rates of chronic
suppression (superior/non-inferior to NAs) and functional cure
• Next steps
– Continue ongoing ≤96 week cohorts
– Phase 2 enabling activities underway作者: newchinabok 时间: 2023-11-20 10:15